Gloria G Guerrero-Manríquez¹, Beatriz Rivera-Aguirre², Dagoberto-Cid Guerrero³, Ge`nesis A Mayorquin-Luna⁴, Carlos O Bermúdez-Jiménez², Cesar Gaitán-Fonseca² and Luis A Aguilera-Galaviz²*

¹Universidad Autónoma de Zacatecas Laboratorio de Inmunobiología, Unidad Académica de Ciencias Biológicas. Zacatecas, Zac, México
²Universidad Autónoma de Zacatecas Unidad Académica de Odontología, Programa de Licenciatura de Médico Cirujano Dentista, Especialidad en Odontopediatría y Maestría en Ciencias Biomédicas, Zacatecas, Zac, México
³Hospital General de Zacatecas, Zacatecas, Zac, México
⁴Instituto Politécnico Nacional, Campus Zacatecas, Zacatecas, Zac, México

*Corresponding Author: Luis A Aguilera-Galaviz, Universidad Autónoma de Zacatecas Unidad Académica de Odontología, Programa de Licenciatura de Médico Cirujano Dentista, Especialidad en Odontopediatría y Maestría en Ciencias Biomédicas, Zacatecas, Zac, México.

Received: May 21, 2024; Published: June 11, 2024

Abstract

Leigh syndrome is a neurodegenerative disease has an incidence of 1:40,000 live births and is the most frequent mitochondrial disease in the first year of life. The clinical presentation is variable and includes psychomotor retardation or regression, acute or acidotic neurological episodes, hypotonic, ataxia, spasticity, movement disorders, and multifocal spongiform degeneration throughout the brain, including the basal ganglia, thalamus, cerebellum, trunk brain, spinal cord and optic nerves which can be seen on MRI, occurs due to mitochondrial dysfunction caused by an inherited genetic defect, associated with bilateral lesions of the central nervous system. Herein we report a case of a child with clinical signs of pneumonia, acidosis, and a psychomotor and neurological disorder. A mutation in the mitochondrial Cytochrome C, encoded by the SURF1 gene as found by DNA sequencing. Interestingly, the pattern of genes up and down regulated affected different pathways and reactions (p-values <<<). From the metabolism of proteins, digestion and absorption to ion channel and oxygen transport, mitochondrial functions, and neuronal system. Altogether the results point, and strengthen the paramount importance of an integrated clinic, genetic and molecular diagnostic to carefully monitor any adverse reaction that can worst the state of health of the individuals.

 Keywords: Mitochondrial Diseases; Leigh; Molecular Techniques; Microarrays; Cytokines

References

1. Gonzalo-Sanz RJN. “Las enfermedades mitocondriales: una clasificación para el siglo”. XXI. (2004): 15-22.
2. Pérez MJL and Montoya JJEDdByBMyC. Universidad de Zaragoza. Miguel Servet. Sistema genético mitocondrial humano 177.50013 (2012): 40-41.
3. Hommes FA., et al. “Leigh's encephalomyelopathy: an inborn error of gluconeogenesis”. Archives of Disease in Childhood 230 (1968): 423-426.
4. Baertling F., et al. “A guide to diagnosis and treatment of Leigh syndrome”. Journal of Neurology, Neurosurgery, and Psychiatry3 (2014): 257-265.
5. Willems JL., et al. “Leigh's encephalomyelopathy in a patient with cytochrome c oxidase deficiency in muscle tissue”. Pediatrics6 (2077): 850-857.
6. Gollihue JL and Rabchevsky AG. “Prospects for therapeutic mitochondrial transplantation”. Mitochondrion 35 (2017): 70-79.
7. Peter B., et al. “Defective mitochondrial protease LonP1 can cause classical mitochondrial disease”. 27.10 (2018): 1743-1753.
8. Tetreault M., et al. “Whole-exome sequencing identifies novel ECHS1 mutations in Leigh syndrome”. 134.9 (2015): 981-991.
9. SALAS PC. “ENFERMEDADES MITOCONDRIALES. GENÉTICA MOLECULAR APLICADA AL DIAGNÓSTICO DE ENFERMEDADES HEREDITARIAS”. 21 (2015): 24-33.
10. Aretini P., et al. “Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome”. BMC Neurology1 (2018): 99.
11. Lopes T., et al. “Leigh syndrome: a case report with a mitochondrial DNA mutation”. 36 (2018): 519-523.
12. Ruhoy IS and Saneto RP. “The genetics of Leigh syndrome and its implications for clinical practice and risk management”. The Application of Clinical Genetics 7 (2014): 221-234.
13. Lopes T., et al. “SÍNDROME DE LEIGH: A PROPÓSITO DE UM CASO CLÍNICO COM MUTAÇÃO NO DNA MITOCONDRIAL”. Revista Paulista de Pediatria (2018): 36.
14. Ogawa E., et al. “Clinical validity of biochemical and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese patients. Journal of inherited metabolic disease”. Journal of Inherited Metabolic Disease 5 (2017): 685-693.
15. Baldo MS., et al. “Molecular basis of Leigh syndrome: a current look”. 15.1 (2020): 1-14.
16. Chang X., et al. “A meta-analysis and systematic review of Leigh syndrome: clinical manifestations, respiratory chain enzyme complex deficiency, and gene mutations”. Medicine5 (2020).
17. Gorman GS., et al. “Mitochondrial diseases”. 2.1 (2016): 1-22.
18. López M., et al. “Microarrays y biochips de ADN: informe de vigilancia tecnológica”. Genoma España; (2002).
19. Vincent A., et al. “Farmacología de los anestésicos locales”. EMC – Podología4 (2019): 1-19.
20. Melis Riera G. “Papel de la disfunción endotelial en la respuesta a la cocaína del flujo coronario y la contractilidad miocárdica”. Universitat de Barcelona; (2003).
21. Hsieh VC., et al. “Mitochondrial Disease and Anesthesia”. Journal of Inborn Errors of Metabolism and Screening 5 (2017): 2326409817707770.
22. Niezgoda J and Morgan PG. “Anesthetic considerations in patients with mitochondrial defects”. Paediatric Anaesthesia9 (2013): 785-793.
23. Szewczyk A and Wojtczak L. “Mitochondria as a pharmacological target”. Pharmacological reviews1 (2002): 101-127.
24. Grouselle D., et al. “Enzyme immunoassays for thyroliberin (TRH) and TRH-elongated peptides in mouse and rat hypothalamus”. Neuropeptides3 (1990): 155-162.
25. Nouette-Gaulain K., et al. “Erythropoietin Protects against Local Anesthetic Myotoxicity during Continuous Regional Analgesia”. Anesthesiology3 (2009): 648-659.
26. SÁNCHEZ JBJPUEdC. Faculdade de Odontologia de Piracicaba. Efeitos da articaína associada a 2-hidroxipropil-β-ciclodextrina ou epinefrina sobre a viabilidade celular de queratinócitos humanos (HaCaT)”. (2014).
27. Hsieh VC., et al. “Screening”. Mitochondrial disease and anesthesia” (2019): 5.
28. Tornero D., et al. “La mitocondria como diana farmacológica en los procesos neurodegenerativos”. Offarm 11 (2002): 98-102.
29. Valverde MdLQ., et al. “Manejo y prevención por parte de los médicos sobre la toxicidad sintética de la anestesia local”. 8.3 (2022): 67.
30. Kalghatgi S., et al. “Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells”. Science Translational Medicine192 (2013): 192ra85.
31. Suárez-Rivero JM., et al. “Mitochondria and Antibiotics: For Good or for Evil?” Biomolecules7 (2021).
32. Santillán-Garzón S., et al. “Diagnóstico molecular de enfermedades genéticas: del diagnóstico genético al diagnóstico genómico con la secuenciación masiva”. (2015): 458-69.
33. Johnson ME., et al. “Mitochondrial injury and caspase activation by the local anesthetic lidocaine”. 101.5 (2004): 1184-1194.
34. Werdehausen R., et al. “Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling”. Anesthesiology1 (2007): 136-143.
35. Herrera-González S., et al. “Efectos adversos de los antibióticos sobre la mitocondria y su asociación con variantes genéticas del ADN mitocondrial en población Mexicana”. 46.4 (2015): 15-24.
36. Lee S., et al. “Epilepsy in Leigh syndrome with mitochondrial DNA mutations”. 10 (2019): 496.

Citation

Citation: Luis A Aguilera-Galaviz., et al. “UP and DOWN Expression of Genes Affects Ion Channels, Oxygen Transport and Mitochondrial Functions in a Case Report of Leigh Syndrome”.Acta Scientific Medical Sciences 8.7 (2024): 76-92.

Copyright

Copyright: © 2024 Luis A Aguilera-Galaviz., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.